A5066442313- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Esophageal Cancer Research and Treatment
- Lung Cancer Diagnosis and Treatment
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Genetic factors in colorectal cancer
- Esophageal and GI Pathology
- Peptidase Inhibition and Analysis
- Pancreatic and Hepatic Oncology Research
- Ovarian cancer diagnosis and treatment
- Immune Cell Function and Interaction
- Renal cell carcinoma treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- PARP inhibition in cancer therapy
- Cancer Treatment and Pharmacology
- Helicobacter pylori-related gastroenterology studies
- Breast Cancer Treatment Studies
- Toxin Mechanisms and Immunotoxins
- Cardiac electrophysiology and arrhythmias
- Advanced Breast Cancer Therapies
- Endoplasmic Reticulum Stress and Disease
- Ion channel regulation and function
National Cancer Center Hospital East
2020-2025
Osaka University
2012-2016
RIKEN Center for Integrative Medical Sciences
2016
National Institute of Mental Health
2014
National Center of Neurology and Psychiatry
2014
University of Yamanashi
2014
Osaka International University
2012
Significance This work, for the first time to our knowledge, distinctly visualizes two different populations of dendritic cells (DCs) essential cytotoxic T-cell generation in skin-draining lymph nodes (SDLNs): migratory CD103 hi DCs that immigrate from other organs including skin and CD8α are resident SDLNs. By imaging spatiotemporal dynamics subsets SDLNs, we find these play roles antigen presentation, with being dramatically more potent interacting CD8 + T cells. work offers critical...
Low concordance between plasma-based and tissue-based tests for determining the RAS mutational status have been reported in some but not all patients with limited-extent metastatic colorectal cancer (mCRC). In this study, we investigated relationship site circulating tumor DNA (ctDNA) detection using ctDNA genotyping, an alternative to tissue genotyping precision oncology.We Guardant360, a next-generation sequencing assay, mCRC single-organ metastasis SCRUM-Japan GOZILA study...
Abstract Although the spleen plays an important role in host defense against infection, mechanism underlying migration of innate immune cells, plasmacytoid dendritic cells (pDCs), into remains ill defined. In this article, we report that pDCs constitutively migrate splenic white pulp (WP) a manner dependent on chemokine receptors CCR7 and CXCR4. CCR7-deficient mice ligand-deficient mice, compared with wild-type (WT) substantially fewer were found periarteriolar lymphoid sheath WP under...
Abstract Purpose: This is a phase Ib trial of TAS-116, an oral HSP90 inhibitor, plus nivolumab for colorectal cancer and other solid tumors. Patients Methods: Enrolled patients received TAS-116 in dose-finding part to estimate the recommended dose. Additional were enrolled dose-expansion part. monotherapy (orally once daily, 80–160 mg) was administered 2 weeks followed by combination with (intravenously every weeks, 3 mg/kg). The primary endpoint dose-limiting toxicities (DLT). We also...
The early detection of gastric neoplasms (GNs) leads to favorable treatment outcomes. latest endoscopic system, EVIS X1, includes third-generation narrow-band imaging (3G-NBI), texture and color enhancement (TXI), high-definition white-light (WLI). Therefore, this randomized phase II trial aimed identify the most promising modality for GN using 3G-NBI TXI.
PURPOSE Genomic profiling programs have been implemented to apply next-generation sequencing (NGS) for facilitating trial enrollment. SCRUM-Japan GI-SCREEN is a large-scale genomic program in advanced gastrointestinal cancers using validated assay with the goal of enrollment targeted clinical trials, generating real-world data, and performing clinicogenomic analysis biomarker discovery. PATIENTS AND METHODS Genotyping tumor tissue samples from 5,743 patients enrolled was centrally performed...
Background/Aim: This study aimed to investigate the efficacy and safety of gemcitabine (GEM) plus nab-paclitaxel (nab-PTX), termed GnP, which is limited, in patients with advanced pancreatic cancer (PC) who show good tolerance GEM monotherapy prior being refractory it. Patients Methods: We retrospectively analyzed data locally or metastatic PC received followed by GnP between December 2014 March 2019, regardless treatment line. Results: A total 14 after becoming were included this study....
PURPOSE Circulating tumor DNA (ctDNA) genotyping on the basis of next-generation sequencing (NGS) may guide targeted therapy for metastatic colorectal cancer (mCRC). However, validity NGS-based ctDNA RAS/BRAF V600E mutation assessment and efficacy anti-EGFR BRAF-targeted therapies results remains unclear. PATIENTS AND METHODS The performance was compared with that a validated polymerase chain reaction–based tissue testing in patients mCRC enrolled GOZILA study, nationwide plasma study....
3102 Background: FGFR alterations are observed in approximately 7% of advanced solid malignancies and associated with poor prognosis resistance to traditional anti-cancer therapy. Despite this, optimal therapeutic strategies inhibitors for most FGFR-altered yet be defined. Circulating tumor DNA (ctDNA) analysis has the potential accurately detect by assessing spatial temporal intratumoral heterogeneity. Methods: We conducted a multicenter, investigator-initiated, phase II basket-type trial,...
5545 Background: Olaparib, a PARP inhibitor, is effective as maintenance therapy for newly diagnosed BRCA-mutated or homologous recombination deficiency (HRD)-positive advanced ovarian cancer and in platinum-sensitive recurrent cancer. Preclinical studies suggest synergy between inhibitors immune checkpoint inhibitors, with demonstrated efficacy patients. However, the safety of this combination neoadjuvant remain uncertain. Methods: This open-label, multicenter pilot study evaluated olaparib...
We investigated the long-term outcomes of lobe-specific nodal dissection (LSD) and systematic (SND) in patients with non-small-cell lung cancer (NSCLC).Patients c-stage I II NSCLC who underwent lobectomy mediastinal were retrospectively analysed. After propensity score matching, we assessed overall survival (OS), recurrence-free (RFS) cumulative incidence death (CID) from primary other diseases.The median follow-up period was 8.4 years. Among 438 score-matched pairs, OS RFS similar between...
Objective: To identify the effects of antipsychotics on QTc prolongation in light age, gender, antipsychotic combination pattern, doses and cytochrome P450 (CYP) mediation, using large database describing treatment patients with schizophrenia Japan. Methods: Using 4176 discharged between April 2004 March 2005 receiving outpatient from 526 psychiatric hospitals Of patients, 1437 were included for analysis. These classified into three groups according to CPZ-equivalent that they received (low,...
98 Background: TMB is a biomarker for immune checkpoint inhibitors (ICIs). Analysis of circulating tumor DNA (ctDNA) has the potential to non-invasively identify pts likely benefit from ICIs by assessing pTMB. We conducted phase II basket trial as part SCRUM-Japan GOZILA umbrella/basket evaluate efficacy and safety nivolumab monotherapy in with advanced GI cancers high Methods: Eligibility criteria included histologically confirmed unresectable or recurrent cancers; ECOG PS 0 1; refractory...
4052 Background: We previously reported anti-tumor activity of regorafenib plus nivolumab for advanced gastric cancer (AGC) patients at a third or later line (1). Recently, first-line with and FOLFOX in AGC showed promising results phase 2 the United States. CapeOX requires less frequent outpatient visits than is preferred Asian countries. investigated safety efficacy chemotherapy including treatment. Methods: Enrolled received (Cohort A) B) Ib part (safety lead-in) to determine recommended...